Effect of CoQ10 on rheumatoid arthritis

Not Applicable

Conditions: Condition 1: Rheumatoid Arthritis. Condition 2: Rheumatoid Arthritis. Condition 3: Rheumatoid Arthritis.
Seropositive rheumatoid arthritis
Other rheumatoid arthritis
Juvenile arthritis

Registration Number: IRCT201311014105N16

Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 50

Inclusion Criteria

Inclusion Criteria:
Disease diagnosis based on ACR criteria by expert; Fixed type and dose of drugs one month before intervention to the end of the study; Under treatment with DMARDs (Hydroxychloroquine, Prednisone, Methotrexate, Sulfasalazine, and ...); Patients with moderate and severe disease; Catching RA disease at least six months ago; Age between 18 to 65 years; Consent to participate in the study
Exclusion criteria:
Simultaneously participate in trials of other investigators; Pregnancy or the decision to become pregnant during the study period; Breastfeeding; Taking contraceptive drugs; Consumption of antioxidant supplements (A, C, E); Consumption of omega-3 fatty acids; Having liver, kidney, thyroid, diabetes, or infectious disease; Taking anticoagulants such as warfarin; Smoking or repeated exposure to smoking; Drug addiction; Not wanting to continue; Less than 70% adherence

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malondialdehyde (MDA). Timepoint: At baseline and 2 months after intervention. Method of measurement: Spectrophotometry.;Matrix metalloproteinase 1 (MMP-1). Timepoint: At baseline and 2 months after intervention. Method of measurement: MMP-1 kit.;Matrix metalloproteinase 3 (MMP-3). Timepoint: At baseline and 2 months after intervention. Method of measurement: MMP-3 kit.;Total antioxidant capacity (TAC). Timepoint: At baseline and 2 months after intervention. Method of measurement: TAC kit.;Interleukin 6 (IL-6). Timepoint: At baseline and 2 months after intervention. Method of measurement: IL-6 kit.;Tumor necrosis factor alpha (TNF-a). Timepoint: At baseline and 2 months after intervention. Method of measurement: TNF-a kit.;Health status. Timepoint: At baseline and 2 months after intervention. Method of measurement: Questionnaire.;Disease activity. Timepoint: At baseline and 2 months after intervention. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
High density lipoprotein (HDL). Timepoint: At baseline and 2 months after intervention. Method of measurement: HDL kit.;Triglyceride (TG). Timepoint: At baseline and 2 months after intervention. Method of measurement: TG kit.;Cholesterol. Timepoint: At baseline and 2 months after intervention. Method of measurement: Cholesterol kit.;Low density lipoprotein (LDL). Timepoint: At baseline and 2 months after intervention. Method of measurement: Calculate with the friedewald equation.;Body mass index (BMI). Timepoint: At baseline and 2 months after intervention. Method of measurement: Calculation.